Pataday, once one of the most commonly prescribed eye allergy drops in the country, is now sitting on the shelf at your local pharmacy — no doctor’s visit required. The Alcon-manufactured drop, which uses the antihistamine olopatadine hydrochloride, received FDA approval for over-the-counter sale starting in 2020, with the strongest formulation, Pataday Once Daily Relief Extra Strength (olopatadine 0.7%), following as the first and only OTC eye allergy drop proven to deliver 24-hour itch relief. For the millions of older adults managing both seasonal allergies and cognitive decline, the ability to grab an effective eye drop without scheduling yet another medical appointment is a genuinely meaningful shift. Pataday is not the only former prescription eye drop to make the jump.
LASTACAFT, an alcaftadine-based antihistamine drop, became available over the counter in March 2022, offering up to 16 hours of relief. And on the prescription side, a new drop called VIZZ was approved in July 2025 for presbyopia — the age-related loss of near vision that affects virtually everyone over 45. This article covers what each of these drops does, who they are appropriate for, how they differ, and what caregivers and older adults should know before using them. The reason this matters for brain health and dementia care readers specifically is straightforward: vision problems in older adults are linked to faster cognitive decline, increased fall risk, and social withdrawal. Anything that lowers the barrier to treating eye discomfort — whether allergic itch or blurry reading vision — has downstream implications for quality of life and independence.
Table of Contents
- Which Prescription Eye Drops Are Now Available Without a Prescription?
- How Olopatadine Works and Why It Took Years to Reach Store Shelves
- Generic Pataday Is Arriving and What That Means for Cost
- Pataday vs. LASTACAFT — Choosing the Right OTC Allergy Drop
- VIZZ for Presbyopia — A Prescription Drop That Helps Aging Eyes Read Again
- What Caregivers Should Know About Administering Eye Drops to Someone With Dementia
- What Comes Next for OTC Eye Care
- Conclusion
- Frequently Asked Questions
Which Prescription Eye Drops Are Now Available Without a Prescription?
The headline product is Pataday, manufactured by Alcon. There are now three OTC formulations available. Pataday Twice Daily Relief contains olopatadine 0.1% (formerly sold by prescription as Patanol). Pataday Once Daily Relief contains olopatadine 0.2% (the original prescription Pataday). And Pataday Once Daily Relief Extra Strength contains olopatadine 0.7%, which was previously available only as the prescription drug Pazeo. All three are approved for ages 2 and older and are indicated for temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.
The second major Rx-to-OTC switch is LASTACAFT, which AbbVie made available without a prescription in March 2022. LASTACAFT uses alcaftadine as its active ingredient rather than olopatadine. It provides eye allergy itch relief in minutes and lasts up to 16 hours — shorter than the Extra Strength Pataday’s 24-hour claim, but still a full waking day for most people. Both products are now available at major retailers including CVS, Walgreens, Target, and Amazon. What has not gone OTC is VIZZ (aceclidine ophthalmic solution 1.44%), which the FDA approved on July 31, 2025. VIZZ treats presbyopia, not allergies, and still requires a prescription. It is worth knowing about because presbyopia affects the same older adult population that this site serves, but do not expect to find VIZZ on a store shelf anytime soon.
How Olopatadine Works and Why It Took Years to Reach Store Shelves
Olopatadine hydrochloride is a dual-action compound. It works as both an antihistamine, blocking the histamine receptors that cause itching, and a mast cell stabilizer, which prevents the release of histamine and other inflammatory chemicals in the first place. This two-pronged mechanism is what made it a preferred prescription choice for years and what distinguishes it from simpler OTC antihistamine drops that only block histamine after it has already been released. The path from prescription to over-the-counter was not quick. Alcon secured the rights to pursue the Rx-to-OTC switch as part of its separation from Novartis in April 2019.
The lower-strength formulations reached OTC shelves by March 2, 2020. The Extra Strength version came later. The regulatory process requires demonstrating that consumers can use the product safely and effectively without a physician’s guidance — a higher bar than simply proving the drug works. However, if you or someone you care for has any eye condition beyond simple allergic itch — glaucoma, chronic dry eye, an eye infection, or recent eye surgery — these OTC drops are not a substitute for medical evaluation. Olopatadine treats allergic itch specifically. Using it to mask symptoms of a different condition can delay proper diagnosis, which is particularly concerning in older adults where eye problems often signal broader health changes.
Generic Pataday Is Arriving and What That Means for Cost
One of the most practical developments for budget-conscious families and caregivers came in January 2026, when the FDA approved Gland Pharma’s OTC generic version of Extra Strength Pataday. That same month, Dr. Reddy’s Laboratories launched olopatadine HCl 0.7% as a first-to-market generic, beating other manufacturers to pharmacy shelves. Brand-name Pataday Extra Strength runs approximately $20 for a 2.5mL bottle, and generic competition should push that price lower over the coming months. For families managing dementia care — where out-of-pocket costs for medications, supplies, and in-home help already run high — a few dollars saved on an eye drop matters more than it might seem. A person with moderate allergies might go through a bottle every few weeks during peak season.
Multiply that across several months and the savings from a generic add up. The generic contains the same active ingredient at the same concentration, so there is no clinical reason to prefer the brand name. That said, watch for differences in inactive ingredients between brand and generic formulations. some older adults have sensitivities to specific preservatives or buffering agents. If someone tolerates brand-name Pataday well, switching to a generic that causes stinging or irritation defeats the purpose. Try one bottle of the generic before buying in bulk.
Pataday vs. LASTACAFT — Choosing the Right OTC Allergy Drop
The two main OTC options have meaningful differences. Pataday Extra Strength provides up to 24 hours of relief with once-daily dosing and uses olopatadine 0.7%. LASTACAFT provides up to 16 hours of relief, also with once-daily dosing, and uses alcaftadine as its active ingredient. Both are approved for ages 2 and older and treat the same basic symptom: itchy eyes from allergens. For someone whose allergies flare primarily during the day, LASTACAFT’s 16-hour window may be entirely sufficient.
But for people who experience nighttime itching — which can disrupt the already fragile sleep patterns common in dementia — the longer duration of Pataday Extra Strength could make a real difference. Sleep disruption in people with Alzheimer’s and other dementias accelerates cognitive decline, so anything that reduces overnight discomfort has outsized value in this population. The tradeoff is price and availability. LASTACAFT may be priced differently depending on the retailer, and individual response varies. Some people simply respond better to alcaftadine than olopatadine, or vice versa. If one product causes irritation or does not seem effective after a few days of consistent use, switching to the other is a reasonable next step before going back to a doctor for a prescription alternative.
VIZZ for Presbyopia — A Prescription Drop That Helps Aging Eyes Read Again
VIZZ is a different category of eye drop entirely, but it is relevant here because presbyopia — the gradual loss of ability to focus on close objects — affects nearly every adult over 45 and is a genuine quality-of-life issue for people with early cognitive changes. VIZZ (aceclidine ophthalmic solution 1.44%), approved by the FDA on July 31, 2025, is the first and only aceclidine-based drop for presbyopia. It works by contracting the iris sphincter muscle to create a sub-2mm pupil, producing a pinhole effect that extends depth of focus and sharpens near vision for up to 10 hours. In Phase 3 clinical trials, 71% of participants achieved a three-line improvement in near vision at 30 minutes and again at 3 hours after dosing. At 10 hours, 40% still maintained that improvement. Those are solid numbers, though they also mean that a meaningful percentage of users will not see dramatic results.
VIZZ requires a prescription and costs approximately $79 per month if purchased directly, or about $66 per month through a three-month supply. GoodRx lists prices as low as $79.99 with a coupon, which is roughly 17% off the average retail price of $96.42. The important limitation: VIZZ causes temporary dim or dark vision, particularly in low-light environments. For an older adult with dementia who already struggles with spatial awareness and fall risk, reduced vision in dim lighting is a serious concern. Headaches and eye redness are also reported side effects. VIZZ is not an appropriate unsupervised solution for someone with significant cognitive impairment, and caregivers should weigh these risks carefully with a physician before starting it.
What Caregivers Should Know About Administering Eye Drops to Someone With Dementia
Getting eye drops into the eyes of a person with moderate to advanced dementia is harder than most people expect. The person may not understand what is happening, may flinch or resist, or may rub their eyes immediately after application — wiping the medication away before it can work. One practical approach is to have the person lie down with eyes closed, place the drop at the inner corner of the closed eye, and then ask them to blink. The drop rolls in naturally with less startle response.
It also helps to establish a consistent routine. Administer the drop at the same time each day, in the same location, with the same verbal cues. Familiar patterns reduce anxiety in people with cognitive impairment. If the person consistently resists, talk to their ophthalmologist — there may be alternative treatments, including oral antihistamines for allergic symptoms, that avoid the eye drop issue entirely.
What Comes Next for OTC Eye Care
The trend toward moving effective, well-studied prescription eye medications to OTC status is likely to continue. The success of Pataday and LASTACAFT has demonstrated that consumers can use these products safely without direct physician oversight, and pharmaceutical companies see the financial incentive in reaching a broader market. LENZ Therapeutics, the maker of VIZZ, has launched a consumer campaign featuring Sarah Jessica Parker called “Make it VIZZable,” signaling that even prescription eye drops are being marketed with a consumer-direct mindset.
For the dementia care community, the broader takeaway is that eye health should not be an afterthought. Vision loss and untreated eye discomfort contribute to confusion, agitation, falls, and social isolation — all of which worsen cognitive decline. The easier it becomes to treat common eye problems, whether through OTC allergy drops or new prescription options for age-related vision changes, the better positioned caregivers are to preserve quality of life for the people they look after.
Conclusion
The shift of Pataday and LASTACAFT from prescription to over-the-counter status represents a genuine convenience for older adults and their caregivers. Pataday Once Daily Relief Extra Strength, with its 24-hour duration and now-available generics from Dr. Reddy’s and Gland Pharma, is the standout option for persistent allergic eye itch. LASTACAFT offers a solid 16-hour alternative.
Meanwhile, VIZZ opens a new door for presbyopia treatment, though its prescription requirement, cost, and side effect profile demand more careful consideration — especially in people with cognitive impairment. If you are caring for someone with dementia who complains of itchy or uncomfortable eyes, start with an OTC olopatadine or alcaftadine drop and see if it helps. If near vision is the problem, bring up VIZZ at the next doctor’s appointment and discuss whether the benefits outweigh the risks given that person’s specific situation. Either way, do not ignore eye complaints — they are often treatable, and treating them can meaningfully improve daily functioning and mood.
Frequently Asked Questions
Is Pataday safe for older adults with dementia?
Pataday (olopatadine) is approved for ages 2 and older and is generally well tolerated. There are no specific contraindications related to dementia. However, if the person is on multiple medications, check with a pharmacist for potential interactions, and monitor for any unusual reactions after the first few uses.
Can I use Pataday and LASTACAFT at the same time?
There is no established safety data on using both simultaneously, and it is generally unnecessary since both treat the same symptom. If one is not working, switch to the other rather than layering them. Consult an eye doctor if neither provides adequate relief.
Does VIZZ require ongoing use or is it a one-time treatment?
VIZZ is a daily-use drop, not a permanent fix. Its near-vision improvement lasts up to 10 hours per dose, so it must be applied each day you want the benefit. If you stop using it, your near vision returns to its previous state.
Are there any eye drops that treat both allergies and presbyopia?
No. Allergy drops like Pataday and LASTACAFT address histamine-mediated itching, while VIZZ addresses the optical mechanics of focusing. They work through completely different mechanisms and treat unrelated conditions. A person could theoretically use both an OTC allergy drop and a prescription presbyopia drop, but should discuss this with their doctor.
How should I store OTC eye drops?
Store at room temperature, away from direct sunlight. Do not use drops past their expiration date, and discard the bottle according to the timeframe specified on the label after first opening — typically within 60 to 90 days. If the solution appears cloudy or discolored, do not use it.
